Susan Minton - Concepedia

Author

Susan Minton

Moffitt Cancer Center

Also Known As

Neuger, Tony, S E Minton, S. E. Minton, Susan E Minton, Susan E. Minton, Susan Minton

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Moffitt Cancer Center University of South Florida University of California, San Francisco NewLink Genetics (United States)Georgetown University

About

Susan Minton is an author at Moffitt Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	617
2	Health Sciences	6	6	210
3	Cell Biology	2	2	70
4	Endocrinology	1	1	16
5	Exercise Physiology	1	1	26

Susan Minton

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells Tanya Gritsko, Ann H. Williams, James Turkson, Clinical Cancer Research	2006	563
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Pamela N. Münster, Kenneth T. Thurn, Scott Thomas, British Journal of Cancer	2011	386
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer Pedro M. Enríquez‐Navas, Yoonseok Kam, Tuhin K. Das, Science Translational Medicine	2016	326
Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression Nills Diaz, Susan Minton, Charles Cox, Clinical Cancer Research	2006	241
Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer Pamela N. Münster, Amy P. Moore, Roohi Ismail‐Khan, Journal of Clinical Oncology	2012	238
Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study Pamela N. Münster, Douglas C. Marchion, Elona Biçaku, Journal of Clinical Oncology	2007	218
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen, Journal of Hematology & Oncology	2014	189
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors Hatem Soliman, Erica L. Jackson, Tony Neuger, Oncotarget	2014	170
Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer Ariosto S. Silva, Yoonseok Kam, Zayar P. Khin, Cancer Research	2012	158
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC Pamela N. Münster, Douglas C. Marchion, Elona Biçaku, Clinical Cancer Research	2009	148

Page 1